NDATRANSDERMALSPRAY
Approved
Jul 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
EVAMIST (estradiol) by Design Pharmaceuticals is estrogen receptor agonists [moa]. Approved for menopause, contraception, vaginal atrophy and 1 more indications. First approved in 2007.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVAMIST is a transdermal estradiol spray approved in 2007 for menopausal vasomotor symptoms and vaginal atrophy. It is an estrogen receptor agonist that delivers bioidentical estradiol through the skin. The product is also used off-label for contraception, aging, cognitive impairment, and metabolic conditions including diabetes and obesity.
$0.347MPart D
LOE ApproachingDeclining
Small commercial footprint ($347K Part D spending, 1,414 claims in 2023) with approaching loss of exclusivity signals a mature, stable team focused on maintaining existing patient base rather than growth expansion.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications (4)
Worked on EVAMIST at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.